481.59
前日終値:
$475.91
開ける:
$475.19
24時間の取引高:
1.36M
Relative Volume:
1.15
時価総額:
$63.13B
収益:
$2.46B
当期純損益:
$-319.09M
株価収益率:
-195.22
EPS:
-2.4669
ネットキャッシュフロー:
$-52.09M
1週間 パフォーマンス:
+3.59%
1か月 パフォーマンス:
+7.62%
6か月 パフォーマンス:
+87.25%
1年 パフォーマンス:
+69.16%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboardsQuarterly Market Summary & Stepwise Entry and Exit Trade Signals - newser.com
Is Alnylam Pharmaceuticals Inc. reversing from oversold territory2025 Top Gainers & Smart Investment Allocation Tips - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.Weekly Profit Summary & Fast Exit and Entry Strategy Plans - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stockMarket Risk Summary & Fast Gain Swing Alerts - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureGlobal Markets & High Return Stock Watch Alerts - newser.com
RNAi Technology Market See Incredible Growth 2025-2032 | Alnylam Pharmaceuticals, OriGene Technologies, Inc. - openPR.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
PD-1 and PD-L1 Inhibitors Clinical Landscape, Key Companies, Therapeutic Evaluation, Treatment Approaches, and Pipeline Insights | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals - Barchart.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesJuly 2025 Retail & High Win Rate Trade Tips - Fundação Cultural do Pará
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsWeekly Trend Summary & Comprehensive Market Scan Insights - newser.com
Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS - Yahoo Finance
Hypertension Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Addpharma Inc., Alnylam Therapeutics, ORPHAI THERAPEUTICS, 35Pharma Inc - Barchart.com
Alnylam Pharmaceuticals (ALNY) extending rally in final stage from April-2025 low - FXStreet
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stock2025 Volatility Report & Free Weekly Watchlist of Top Performers - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stock2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flows2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Is it time to cut losses on Alnylam Pharmaceuticals Inc.Treasury Yields & Smart Investment Allocation Insights - newser.com
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorEarnings Miss & High Return Trade Opportunity Guides - newser.com
Alnylam Pharmaceuticals Inc Stock Analysis and ForecastMarket Liquidity Analysis & Free Rapid Profit Acceleration - earlytimes.in
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Is Alnylam Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Action & High Accuracy Swing Entry Alerts - newser.com
Bernstein previews biotech earnings, expects Alnylam and Regeneron to beat - Investing.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.Exit Point & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-10-27 00:10:20 - newser.com
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
大文字化:
|
ボリューム (24 時間):